Tangram Doses First Participant in TGM-148 Phase 1 Trial
Tangram says the first participant has received TGM-148 in a Phase 1 trial evaluating the experimental RNAi drug for bleeding disorders.
Tangram says the first participant has received TGM-148 in a Phase 1 trial evaluating the experimental RNAi drug for bleeding disorders.